Targeting the Type I Interferon Pathway in Glomerular Kidney Disease: Rationale and Therapeutic Opportunities

This publication has 75 references indexed in Scilit:

• Heterogeneity and functions of the 13 IFN‐α subtypes – lucky for some?
  European Journal of Immunology, 2023
• Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial
  Arthritis & Rheumatology, 2022
• Complete remission of tip lesion variant focal segmental glomerulosclerosis (FSGS) with the Janus Kinase (JAK) inhibitor tofacitinib
  CEN Case Reports, 2021
• APOL1 C-Terminal Variants May Trigger Kidney Disease through Interference with APOL3 Control of Actomyosin
  Cell Reports, 2020
• Monogenic lupus: Dissecting heterogeneity
  Autoimmunity Reviews, 2019
• Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment
  Journal of Clinical Immunology, 2018
• Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: Results of a phase I, placebo‐controlled, double‐blind, dose‐escalation study
  Arthritis & Rheumatism, 2012
• Association of endogenous anti–interferon‐α autoantibodies with decreased interferon‐pathway and disease activity in patients with systemic lupus erythematosus
  Arthritis & Rheumatism, 2011
• Neutralization of interferon‐α/β–inducible genes and downstream effect in a phase I trial of an anti–interferon‐α monoclonal antibody in systemic lupus erythematosus
  Arthritis & Rheumatism, 2009
• Tubuloreticular structures and cylindrical confronting cisternae: A review
  Human Pathology, 1989